US-based 22nd Century Group has acquired RX Pharmatech (RXP), a leading cannabinoid distributor in the UK that offers 1,276 food applications. The deal includes a cash and stock payment of $650,000 (approximately RMB 4.41 million) upfront, as well as equity payouts over a three-year period based on revenue.
The acquisition will ensure direct entry of our CBD products into the European market," said Mish, CEO of 22nd Century Group. "RXP has developed efficient application and compliance plans, ensuring approval for 1,276 new food applications for CBD products in the first round. As we move forward, we look forward to leveraging their leadership team's rich experience in the cannabis industry and strong relationships with UK and EU regulatory agencies.
Mish continued to say, "We expect that the acquisition of RXP will enhance the group's operational efficiency, leading to improvements in revenue and gross profit margins. In particular, by adding RXP to our recently opened distribution channels in the Netherlands, we will be able to expand our business scale and seize a larger market share in the ever-growing European consumer goods market.
RXP offers a range of products, including CBD isolates, as well as various finished products such as chewing gum, oil, droppers, candy, tinctures, sprays, and capsules.
The 22nd Century Group is a brand company that sells VLN cigarettes, holds valuable biotechnology intellectual property (IP), and offers highly specialized factory production lines in global end markets.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
